加载中
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
前收盘价
US$1.41
−US$0.11 · -7.24%
盘后
US$1.41
US$0.00 · 0.00%
10月12日 17:10 ET
盘中时间采用ET。市场数据可能有所延迟。
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
日内区间
当前US$1.41
52周区间
当前US$1.41
盘中时间采用ET。市场数据可能有所延迟。
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
日内区间
当前US$1.41
52周区间
当前US$1.41
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 114.4万 USD | 125.7万 USD | 65万 USD | 128.1万 USD |
| 毛利 | — | −114.4万 USD | −125.7万 USD | −65万 USD | −128.1万 USD |
| 研究与开发 | 6987.7万 USD | 5738.3万 USD | 5462.8万 USD | 5167.3万 USD | 3618.6万 USD |
| 销售、一般及管理费用 | 1632.9万 USD | 2692.1万 USD | 2424.7万 USD | 2471.7万 USD | 2082.6万 USD |
| 营业费用 | 8620.6万 USD | 8430.4万 USD | 7887.5万 USD | 7639万 USD | 5701.2万 USD |
| 利息收入 | 633.7万 USD | 1065.5万 USD | 1117.1万 USD | 362.7万 USD | 44.9万 USD |
| 折旧和摊销 | 13.3万 USD | 114.4万 USD | 125.7万 USD | 31.5万 USD | 30.7万 USD |
| 营业利润 | −8620.6万 USD | −8544.8万 USD | −8013.2万 USD | −7704万 USD | −5829.3万 USD |
| 净利润 | −7774.2万 USD | −5870.9万 USD | −6896万 USD | −7331.7万 USD | −5784.6万 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
评级样本有限，仅4项
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI179.93万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF54.74万0.00%954亿 USD0.05%US$233.52-0.63%
iShares Micro-Cap ETFIWC23.12万0.02%13.17亿 USD0.60%US$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM11万0.10%1.16亿 USD0.73%US$15.8484-0.58%
Avantis Total Equity Markets ETF 1AVTM7168.32—7.94亿 USD0.23%US$55.51-0.18%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis Total Equity Markets ETF 1AVTMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
